[{"orgOrder":0,"company":"Aksigen Hospital Care","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Bromelain","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Aksigen Hospital Care","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aksigen Hospital Care \/ Sun Pharmaceutical Industries Limited","highestDevelopmentStatusID":"12","companyTruncated":"Aksigen Hospital Care \/ Sun Pharmaceutical Industries Limited"}]

Find Clinical Drug Pipeline Developments & Deals for Trypsin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Through the acquisition, Sun Pharma strengthen its anti-inflammatory portfolio by adding Disperzyme (bromelain), Disperzyme-CD and Phlogam from Aksigen Hospital Care.

                          Brand Name : Disperzyme

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          January 30, 2023

                          Lead Product(s) : Bromelain,Trypsin,Rutin

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved

                          Sponsor : Sun Pharmaceutical Industries Limited

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank